Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Madrigal Pharmaceuticals (MDGL) Return on Equity (2019 - 2025)

Historic Return on Equity for Madrigal Pharmaceuticals (MDGL) over the last 13 years, with Q3 2025 value amounting to 0.43%.

  • Madrigal Pharmaceuticals' Return on Equity rose 2000.0% to 0.43% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.43%, marking a year-over-year increase of 2000.0%. This contributed to the annual value of 0.8% for FY2024, which is 4400.0% up from last year.
  • Latest data reveals that Madrigal Pharmaceuticals reported Return on Equity of 0.43% as of Q3 2025, which was up 2000.0% from 0.4% recorded in Q2 2025.
  • Over the past 5 years, Madrigal Pharmaceuticals' Return on Equity peaked at 0.4% during Q2 2025, and registered a low of 5.82% during Q3 2022.
  • For the 5-year period, Madrigal Pharmaceuticals' Return on Equity averaged around 1.67%, with its median value being 0.94% (2021).
  • As far as peak fluctuations go, Madrigal Pharmaceuticals' Return on Equity crashed by -48800bps in 2022, and later skyrocketed by 48900bps in 2024.
  • Madrigal Pharmaceuticals' Return on Equity (Quarter) stood at 1.12% in 2021, then tumbled by -153bps to 2.84% in 2022, then skyrocketed by 38bps to 1.75% in 2023, then soared by 65bps to 0.61% in 2024, then grew by 29bps to 0.43% in 2025.
  • Its last three reported values are 0.43% in Q3 2025, 0.4% for Q2 2025, and 0.53% during Q1 2025.